Loading organizations...
§ Public · La Jolla, CA, USA
Janux Therapeutics is a technology company.
Janux Therapeutics develops next-generation immunotherapies to precisely target and treat cancer and autoimmune diseases. The company leverages proprietary TRACTr, TRACIr, and ARM platforms to engineer novel drug candidates designed to elicit potent and durable immune responses. This advanced technical approach aims to overcome the systemic safety limitations often associated with current immunotherapies, delivering more selective and effective treatments.
David Campbell, Ph.D., founded Janux in 2017, serving as its President and Chief Executive Officer. His insight, combined with the team's deep experience in drug development and protein engineering, identified a critical need for therapies that could selectively modulate T cells. The company’s foundational premise is to stimulate the immune system to fight disease while avoiding broad, off-target adverse effects.
Janux Therapeutics focuses on patients suffering from difficult-to-treat cancers and autoimmune conditions. The company's overarching vision is to provide safe and highly effective drugs that guide the immune system to eradicate disease. By prioritizing minimized systemic toxicity, Janux strives to offer impactful therapeutic options for significant unmet medical needs.
Janux Therapeutics has raised $186.0M across 2 funding rounds.
Janux Therapeutics has raised $186.0M in total across 2 funding rounds.
Janux Therapeutics has raised $186.0M across 2 funding rounds. Most recently, it raised $130.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2021 | $130M Series B | RA Capital Management | Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal BioVenture Partners, Rivervest, Jonathan Root, Heather Preston, Bregua Corporation, BVF Partners, EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital, Surveyor Capital | Announced |
| Mar 1, 2021 | $56M Series A | Avalon Ventures | Domain Associates, OrbiMed, Osage University Partners, Pivotal BioVenture Partners, Rivervest, Jonathan Root, Heather Preston, Bregua Corporation, Correlation Ventures, Jake Simson | Announced |
Janux Therapeutics has raised $186.0M in total across 2 funding rounds.
Janux Therapeutics's investors include RA Capital Management, Avalon Ventures, Domain Associates, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RiverVest, Jonathan Root, Heather Preston, Bregua Corporation, BVF Partners, EcoR1 Capital.
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies, primarily bispecific T cell engagers using its proprietary TRACTr platform, to treat cancer and autoimmune diseases by directing the immune system against tumors while minimizing systemic toxicities.[2][3][5] It serves cancer patients, starting with solid tumors like prostate cancer via its lead candidate JANX001 (PSMA-targeted TRACTr) in Phase 1 trials, and addresses unmet needs in immunotherapy by overcoming limitations of traditional T cell engagers through tumor-activated mechanisms, masks, and albumin binding for safer, more durable responses.[1][3][5] Growth momentum includes its 2021 IPO, first program entering clinic in 2022, a robust pipeline (e.g., EGFR, TROP2 targets), and a Merck collaboration, positioning it as a key player in oncology biotech from its San Diego base with ~71 employees.[2][5][7]
Founded in 2017, Janux emerged from a vision to pioneer next-generation T cell immunotherapies, building on proprietary platforms like TRACTr to improve upon existing TCEs for cancer.[2][5] Key scientific leadership includes Chief Scientific Officer Dr. Tommy Diraimondo, whose PhD expertise drives discovery and pipeline advancement from preclinical to clinical stages.[1] The company achieved early traction with its June 2021 IPO and dosed the first patient in its lead prostate cancer trial (JANX001) in late 2022, alongside IND plans for additional programs and a strategic research deal with Merck on two targets.[2][5] This data-driven, collaborative culture has fueled rapid progress in San Diego's biotech hub.[2][7][8]
Janux stands out in immunotherapy through these key strengths:
Janux rides the cancer immunotherapy wave, particularly T cell engagers, amid surging demand for precise, tolerable treatments in a $100B+ oncology market driven by aging populations and immunotherapy breakthroughs like checkpoint inhibitors.[1][2][5] Timing aligns with post-2020 advances in bispecifics (e.g., approved TCEs), where Janux's masked, tumor-conditional tech addresses key pain points like toxicity, enabling broader solid tumor applications beyond liquid cancers.[3][5] Favorable forces include biotech funding recovery, regulatory nods for novel modalities, and partnerships like Merck's, amplifying its influence; it contributes to San Diego's ecosystem by innovating safer TCEs, potentially reshaping standards for immuno-oncology and autoimmune therapies.[2][7][8]
Janux is poised for pipeline catalysts, with Phase 1 data readouts for JANX001 expected soon, potential INDs/expansions for EGFR/TROP2, and Merck milestones driving value in 2026+.[1][3][5] Trends like AI-accelerated discovery, combo therapies, and autoimmune extensions will shape its path, evolving it from clinical-stage innovator to potential multi-product leader if safety/durability holds. As immunotherapy matures, Janux's platforms could transform cancer care, delivering the durable responses that redefine patient lives—echoing its mission to guide immune systems against disease without compromise.[2][4]